Search

Your search keyword '"Kawaoka, Yoshihiro"' showing total 9 results
Start Over Author "Kawaoka, Yoshihiro" Topic antiviral agents Language english Journal new england journal of medicine
9 results on '"Kawaoka, Yoshihiro"'

2. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.

Author

Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann PJ, and Kawaoka Y

Subjects
Humans, Treatment Outcome, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, COVID-19 virology, COVID-19 Drug Treatment, SARS-CoV-2 drug effects
Published
2023
Full Text
View/download PDF

3. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.

Author

Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, and Kawaoka Y

Subjects
Humans, In Vitro Techniques, Antibodies, Viral immunology, Antiviral Agents immunology, Antiviral Agents pharmacology, Vaccine Efficacy, SARS-CoV-2 drug effects, SARS-CoV-2 immunology, COVID-19 genetics, COVID-19 immunology, COVID-19 virology
Published
2022
Full Text
View/download PDF

4. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.

Author

Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, and Kawaoka Y

Subjects
Antibodies, Viral drug effects, Antibodies, Viral immunology, Humans, Antibodies, Neutralizing drug effects, Antibodies, Neutralizing immunology, Antiviral Agents immunology, Antiviral Agents therapeutic use, COVID-19 genetics, COVID-19 immunology, SARS-CoV-2 drug effects, SARS-CoV-2 genetics, SARS-CoV-2 immunology, COVID-19 Drug Treatment
Published
2022
Full Text
View/download PDF

5. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.

Author

Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, and Kawaoka Y

Subjects
Antibodies, Viral immunology, Humans, Vaccine Efficacy, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing therapeutic use, Antiviral Agents therapeutic use, COVID-19 immunology, Immunologic Factors therapeutic use, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
Published
2022
Full Text
View/download PDF

6. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.

Author

Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, and Kawaoka Y

Subjects
Humans, Spike Glycoprotein, Coronavirus, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
Published
2022
Full Text
View/download PDF

7. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.

Author

Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, and Kawaoka Y

Subjects
Antibodies, Monoclonal therapeutic use, Antiviral Agents therapeutic use, Enzyme-Linked Immunosorbent Assay, Mutation, Neutralization Tests, SARS-CoV-2 genetics, COVID-19 Drug Treatment, Antibodies, Monoclonal pharmacology, Antiviral Agents pharmacology, SARS-CoV-2 drug effects
Published
2022
Full Text
View/download PDF

8. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.

Author

Emi Takashita, Selya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Ito, Mutsumi, Uraki, Ryuta, Halfmann, Peter, Watanabe, Shinji, Takeda, Makoto, Hasegawa, Hideki, Imai, Masaki, and Kawaoka, Yoshihiro

Subjects
*IMMUNOGLOBULINS, *ANTIVIRAL agents, *RESEARCH funding, *VIRAL antibodies
Published
2022
Full Text
View/download PDF

9. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.

Author

Emi Takashita, Seiya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M, Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, and Kawaoka, Yoshihiro

Subjects
*IMMUNOGLOBULINS, *MONOCLONAL antibodies, *ANTIVIRAL agents, *VIRAL antibodies
Abstract

The article discusses The data from our trial suggest that dulaglutide , if ultimately approved for pediatric use, may offer advantages not only with regard to glycemic control but also with regard to its frequency and method of administration. Weekly administration with a device that does not require reconstitution steps or needle handling and that has shown favorable ease-of-use characteristics in preference studies involving.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results